Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Should non-nucleoside reverse transcriptase inhibitors be combined?

Bregt S Kappelhoff1, Alwin D R Huitema, Jos H Beijnen

  • 1Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. APBKP@SLX.NL

Drugs in R&D
|March 22, 2005
PubMed
Summary

Dual non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens for HIV treatment show similar efficacy to single NNRTI regimens but increase adverse events. These combinations are less desirable than other available HIV treatment options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network.

Ear and hearing·2026
Same author

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026
Same author

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
Same author

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with <i>ALK-</i>Positive Non-Small Cell Lung Cancer.

Cancer communications (London, England)·2026
Same author

Transfer of trastuzumab and pertuzumab into human breast milk: a case report.

Cancer chemotherapy and pharmacology·2026
Same author

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

European journal of cancer (Oxford, England : 1990)·2026

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • An unmet need exists for improved HIV treatment regimens with better dosing, tolerability, and efficacy.
  • Preclinical data suggested that combining two non-nucleoside reverse transcriptase inhibitors (NNRTIs) could meet this need.
  • Clinical studies yielded mixed results regarding the mechanism, pharmacokinetics, efficacy, and toxicity of dual NNRTI regimens.

Purpose of the Study:

  • To evaluate the efficacy and safety of dual NNRTI regimens compared to single NNRTI regimens in HIV-infected patients.
  • To assess the virological and immunological outcomes of combination NNRTI therapy.
  • To determine the incidence of adverse events associated with dual NNRTI use.

Main Methods:

  • Review of clinical studies investigating dual NNRTI regimens in HIV treatment.

Related Experiment Videos

  • Analysis of virological and immunological data from these studies.
  • Assessment of adverse event profiles, including hepatitis, rash, and CNS toxicity.

    • Main Results:

    • Dual NNRTIs demonstrated additive or synergistic in vitro effects on HIV-1 reverse transcriptase and replication, though antagonism was also noted.
    • Nevirapine co-administration decreased efavirenz exposure due to induced metabolism.
    • Dual NNRTI regimens showed similar virological and immunological success compared to single NNRTI regimens in treatment-naive and pretreated patients.
    • However, dual NNRTI regimens were associated with a higher frequency of adverse events, including hepatitis, rash, and CNS/psychiatric disorders.

    Conclusions:

    • Regimens combining nevirapine and efavirenz offer comparable antiviral and immunological efficacy to single NNRTI regimens.
    • The combination of two NNRTIs leads to an increased incidence of adverse events.
    • Dual NNRTI therapy is considered less desirable than alternative effective HIV treatment options.